Stock Track | Immunome Inc. Surges 5% on Positive Analyst Ratings and Revenue Beat

Stock Track08-14

Shares of Immunome Inc. (IMNM) rallied over 5% in intraday trading on Monday, driven by a wave of positive analyst ratings and a better-than-expected revenue performance in the company's latest quarterly results.

Several Wall Street analysts issued bullish ratings and price target revisions for IMNM stock. Piper Sandler maintained an Overweight rating with a $23 price target, while Wedbush assigned a Buy rating and set a $33 price target. Another analyst from Leer reiterated a Buy rating, citing promising clinical trials and strategic growth prospects for the healthcare company.

Additionally, Immunome reported its Q2 2024 financial results, with revenue of $2.37 million beating analysts' expectations by $0.5 million, although the company's GAAP EPS of -$0.60 missed estimates by $0.17. Immunome's cash position remained strong, with cash, cash equivalents, and marketable securities totaling $278.4 million as of June 30, 2024, providing a runway expected to extend into 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1116641493?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-14 00:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116641493","market":"hk","top_or_hot":-1,"title":"Stock Track | Immunome Inc. Surges 5% on Positive Analyst Ratings and Revenue Beat","media":"Stock Track","content":"<p>Shares of Immunome Inc. (IMNM) rallied over 5% in intraday trading on Monday, driven by a wave of positive analyst ratings and a better-than-expected revenue performance in the company's latest quarterly results.</p>\n\n<p>Several Wall Street analysts issued bullish ratings and price target revisions for IMNM stock. Piper Sandler maintained an Overweight rating with a $23 price target, while Wedbush assigned a Buy rating and set a $33 price target. Another analyst from Leer reiterated a Buy rating, citing promising clinical trials and strategic growth prospects for the healthcare company.</p>\n\n<p>Additionally, Immunome reported its Q2 2024 financial results, with revenue of $2.37 million beating analysts' expectations by $0.5 million, although the company's GAAP EPS of -$0.60 missed estimates by $0.17. Immunome's cash position remained strong, with cash, cash equivalents, and marketable securities totaling $278.4 million as of June 30, 2024, providing a runway expected to extend into 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Immunome Inc. Surges 5% on Positive Analyst Ratings and Revenue Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Immunome Inc. Surges 5% on Positive Analyst Ratings and Revenue Beat\n</h2>\n\n<h4 class=\"meta\">\n\n2024-08-14 00:28 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Immunome Inc. (IMNM) rallied over 5% in intraday trading on Monday, driven by a wave of positive analyst ratings and a better-than-expected revenue performance in the company's latest ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMNM","symbol_name":"Immunome Inc.","start_time":0,"source_url":"","article_id":"1116641493","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116641493","pubTimestamp":1723566507,"sourceInfo":null,"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Immunome Inc.  rallied over 5% in intraday trading on Monday, driven by a wave of positive analyst ratings and a better-than-expected revenue performance in the company's latest quarterly results.Several Wall Street analysts issued bullish ratings and price target revisions for IMNM stock. Piper Sandler maintained an Overweight rating with a $23 price target, while Wedbush assigned a Buy rating and set a $33 price target. Another analyst from Leer reiterated a Buy rating, citing promis","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMNM":"Immunome Inc."},"translate_title":"股票追踪Immunome Inc.因分析师积极评级和收入增长而飙升5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMNM":1},"content_text":"Shares of Immunome Inc. (IMNM) rallied over 5% in intraday trading on Monday, driven by a wave of positive analyst ratings and a better-than-expected revenue performance in the company's latest quarterly results.\nSeveral Wall Street analysts issued bullish ratings and price target revisions for IMNM stock. Piper Sandler maintained an Overweight rating with a $23 price target, while Wedbush assigned a Buy rating and set a $33 price target. Another analyst from Leer reiterated a Buy rating, citing promising clinical trials and strategic growth prospects for the healthcare company.\nAdditionally, Immunome reported its Q2 2024 financial results, with revenue of $2.37 million beating analysts' expectations by $0.5 million, although the company's GAAP EPS of -$0.60 missed estimates by $0.17. Immunome's cash position remained strong, with cash, cash equivalents, and marketable securities totaling $278.4 million as of June 30, 2024, providing a runway expected to extend into 2026.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1116641493"}